Integrated Healing Medicine and Wellness
- PRP Therapy
- Arthritis Treatment
- Peptide Therapy
- Stem Cell Therapy
San Francisco, CA
Stem cell therapy marketing in San Francisco spans orthopedic injectables, cash-pay regenerative suites, and longevity clinics that also pitch exosomes or PRP under neighboring labels. Mission, SOMA, Marina, Pac Heights, and Peninsula spillover all show up in Directory filters. "Stem cell" on a menu can mean very different products, processing steps, and FDA-framed claims.
This hub lists Directory clinics for San Francisco and stem cell therapy. Inclusion is not an endorsement. Listing order is not paid ranking. Regenerated.com is free for patients. Featured slots stay labeled; Verified means credential checks, not spend.
Ask what tissue source they use, how cells are processed, whether the offer is autologous or allogeneic, what outcomes they track, and how they describe regulatory status in plain language. UCSF and CPMC brands are nearby institutional gravity, not a stamp on every private regenerative menu. Prefer clinicians who document consent and evidence grades rather than before/after galleries alone.
Before you trust badges or counts on this page, read How to read a Regenerated city hub and Featured vs Verified vs organic. Then return here for local listings.
Regulatory context
California cellular therapy providers are subject to 21 CFR Part 1271. Minimally manipulated human cells, tissues, and cellular and tissue-based products used for homologous use are regulated under Section 361 without premarket approval. Products that are more than minimally manipulated, used non-homologously, or combined with a drug or device are regulated as biologics under Section 351 and require an IND for clinical use or a BLA for marketing. Adipose-derived stromal vascular fraction, culture-expanded mesenchymal stem cells, and exosomes used for orthopedic, cosmetic, neurologic, and longevity indications are generally Section 351 products.
California has been a focal point of federal enforcement. In United States v California Stem Cell Treatment Center (2022), the Ninth Circuit upheld FDA authority to regulate stromal vascular fraction as a Section 351 drug, resulting in a permanent injunction against the clinic. The FDA has issued multiple warning letters to California providers marketing stem cell and exosome therapies. The Medical Board of California has disciplined physicians for false advertising under BPC 651 and for administering unapproved biologics. The California Department of Public Health enforces tissue bank licensing. Class-action consumer suits against regenerative clinics have produced settlements.
Available here
Nationwide
Stem Cell Therapy clinics across the US